Pasar al contenido principal

ENFERMEDADES NEUROMETABOLICAS RARAS: DE LA INVESTIGACION EN NUEVOS MODELOS DE ENFERMEDAD A TERAPIAS DIRIGIDAS

PID2022-137238OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional analysis of novel variants identified in cis in the PCCB gene in a patient with propionic acidemia

  • Martínez-Pizarro, Ainhoa
  • Calmels, Nadège
  • Schalk, Audrey
  • Wicker, Camille
  • Richard, Eva
  • Desviat, Lourdes R.
Next-generation sequencing has improved the diagnosis of inborn errors of metabolism, allowing rapid confirmation of cases detected by clinical/biochemical studies or newborn screening. The challenge, however, remains for establishing the pathogenicity of the identified variants, especially for novel missense changes or small in-frame deletions. In this work we report a propionic acidemia patient exhibiting a severe neonatal form with coma and hyperammonaemia. Genetic analysis identified the previously described pathogenic PCCB variant p.R512C in the maternal allele and two novel PCCB variants in cis in the paternal allele, p.G246del and p.S322F. Expression analysis in a eukaryotic system confirmed the deleterious effect of the novel missense variant and of the one amino acid deletion, as they both exhibited reduced protein levels and reduced or null PCC activity compared to the wild-type construct. Accordingly, the double mutant resulted in no residual activity. This study increases the knowledge of the genotype-phenotype correlations in the rare disease propionic acidemia and highlights the necessity of functional analysis of novel variants to understand their contribution to disease severity and to accurately classify their pathogenic status. In conclusion, two novel PCCB pathogenic variants have been identified, expanding the current mutational spectrum of propionic acidemia., This work was funded by Spanish Ministry of Science and Innovation and European Regional Development Fund (grants PID2019-105344RB-I00/AEI/10.13039/501100011033 and PID2022-137238OB-I00) and by Fundación Ramón Areces (grant from XX National Call 2020). Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PAH deficient pathology in humanized c.1066-11G>A phenylketonuria mice

  • Martínez-Pizarro, Ainhoa
  • Picó, Sara
  • López-Márquez, Arístides
  • Rodríguez-López, Claudia
  • Montalvo, Elena
  • Álvarez, Mar
  • Castro, Margarita
  • Ramón-Maiques, Santiago
  • Pérez, Belén
  • Lucas, José J.
  • Richard, Eva
  • Desviat, Lourdes R.
16 páginas, 8 figuras, We have generated using CRISPR/Cas9 technology a partially humanized mouse model of the neurometabolic disease phenylketonuria (PKU), carrying the highly prevalent PAH variant c.1066-11G>A. This variant creates an alternative 3' splice site, leading to the inclusion of 9 nucleotides coding for 3 extra amino acids between Q355 and Y356 of the protein. Homozygous Pah c.1066-11A mice, with a partially humanized intron 10 sequence with the variant, accurately recapitulate the splicing defect and present almost undetectable hepatic PAH activity. They exhibit fur hypopigmentation, lower brain and body weight and reduced survival. Blood and brain phenylalanine levels are elevated, along with decreased tyrosine, tryptophan and monoamine neurotransmitter levels. They present behavioral deficits, mainly hypoactivity and diminished social interaction, locomotor deficiencies and an abnormal hind-limb clasping reflex. Changes in the morphology of glial cells, increased GFAP and Iba1 staining signals and decreased myelinization are observed. Hepatic tissue exhibits nearly absent PAH protein, reduced levels of chaperones DNAJC12 and HSP70 and increased autophagy markers LAMP1 and LC3BII, suggesting possible coaggregation of mutant PAH with chaperones and subsequent autophagy processing. This PKU mouse model with a prevalent human variant represents a useful tool for pathophysiology research and for novel therapies development., This work was funded by Spanish Ministry of Science Innovation and Universities MICIU/AEI and European Regional Development Fund (grants PID2019-105344RB-I00/AEI/10.13039/501100011033 and PID PID2022-137238OB-I00/AEI/10.13039/501100011033), by Fundación Ramón Areces (XX National Call 2020) and from TaNeDS Europe 2017 (Daichii Sankyo) research grant. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring RNA therapeutics for urea cycle disorders

  • Richard, Eva
  • Martínez-Pizarro, Ainhoa
  • Desviat, Lourdes R.
RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods. Different therapeutic RNA modalities have shown promise to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. Currently, there are 22 RNA-based drugs approved for clinical use, including the COVID-19 mRNA vaccines, whose unprecedented worldwide success has meant a definitive boost in the RNA research field. Urea cycle disorders (UCD), liver diseases with high mortality and morbidity, may benefit from the progress achieved, as different genetic payloads have been successfully targeted to liver using viral vectors, N-acetylgalactosamine (GalNAc) conjugations or lipid nanoparticles (LNP). This review explores the potential of RNA-based medicines for UCD and the ongoing development of applications targeting specific gene defects, enzymes, or transporters taking part in the urea cycle. Notably, LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency, in the latter case has progressed to the clinical trials phase., This work was funded by grant PID2022-137238OB-100funded by MICIU/AEI/10.13039/501100011033/ and byERDF A way of making Europe. Centro de BiologíaMolecular Severo Ochoa receives an institutional grantfrom Fundaci on Ram on Areces, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel CRISPR-Cas9 iPSC knockouts for PCCA and PCCB genes: advancing propionic acidemia research

  • García-Tenorio, Emilio M
  • Álvarez, Mar
  • Gallego-Bonhomme, Mónica
  • Desviat, Lourdes R
  • Richard, Eva
Propionic acidemia (PA) is a rare autosomal recessive metabolic disorder caused by mutations in the PCCA and PCCB genes, which encode subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC). This enzyme deficiency leads to the accumulation of toxic metabolites, resulting in severe metabolic dysfunction. To create ideal in vitro disease models of PA with isogenic controls and provide a robust platform for therapeutic research, we generated two induced pluripotent stem cell (iPSC) lines with knockout (KO) mutations in the PCCA and PCCB genes using CRISPR-Cas9 gene editing in a healthy control iPSC line. The KO iPS cells were successfully established and characterized, confirming the presence of frameshift insertions and deletions in each target gene, as well as the loss of the corresponding transcript, protein expression, and activity. Additionally, the generated iPSC lines exhibit hallmark characteristics of pluripotency, including the potential to differentiate into all three germ layers. Our PCCA and PCCB KO iPSC models provide a valuable tool for studying the molecular mechanisms underlying PA and hold potential for advancing new therapeutic approaches., PAF113/Propionic Acidemia Foundation PID2022-137238OB-100/Ministerio de Ciencia e Innovación, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic flux analysis in hiPSC-CMs reveals insights into cardiac dysfunction in propionic acidemia

  • Richard, Eva
  • Marchuk, Hannah
  • Álvarez, Mar
  • He, Wentao
  • Chen, Xiaoxin
  • Desviat, Lourdes R.
  • Zhang, Guo-Fang
Propionic acidemia is an inborn error of metabolism caused by mutations in either the PCCA or PCCB genes. Patients with propionic acidemia experience a range of complications, including life-threatening cardiac dysfunctions. However, the pathological mechanisms underlying propionic acidemia-associated cardiac diseases remain largely unknown. To gain insights into the metabolic alterations in propionic acidemia, we studied human induced pluripotent stem cell-derived cardiomyocytes generated from a patient with propionic acidemia with two pathogenic PCCA mutations (p.Cys616_Val633del and p.Gly477Glufs9*) and from a healthy individual. Using stable isotope-based metabolic flux analysis, we confirmed that the PCCA mutations lead to impaired propionyl-CoA carboxylase activity in human induced pluripotent stem cell-derived cardiomyocytes. In addition to being converted to propionylcarnitine, the accumulated propionyl-CoA can also be hydrolyzed to propionate and exported out of the cell, serving as a secondary “pressure valve” to regulate cellular propionyl-CoA levels. Interestingly, the deficiency of propionyl-CoA carboxylase was found to shift fuel metabolism from fatty acid oxidation to increased glucose metabolism human in induced pluripotent stem cell-derived cardiomyocytes from patients with propionic acidemia. This metabolic switch is less energy-efficient and may contribute to the development of chronic cardiac dysfunction in patients with propionic acidemia., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Propionic Acidemia Foundation awards: to G.F.Z. and PAF113 to E. R., NIH R01 AA030026 and NIH R21TR005163 to X.C and G.F.Z, the Fundación Ramón Areces (XX National Call 2020) to E.R. and the MICIU/AEI/https://doi.org/10.13039/501100011033/ and ERDF A way of making Europe (PID2022-137238OB-100) to L.R.D. and E.R. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces and is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Renal phenotyping in a hypomorphic murine model of propionic aciduria reveals common pathomechanisms in organic acidurias

  • Schumann, Anke
  • Martinez-Pizarro, Ainhoa
  • Richard, Eva
  • Schell, Christoph
  • Kössinger, Anna Laura
  • Zeyer, Karina A.
  • Tholen, Stefan
  • Schilling, Oliver
  • Barry, Michael
  • Neubauer, Björn
  • Köttgen, Michael
  • Hannibal, Luciana
  • Desviat, Lourdes R.
  • Spiekerkötter, Ute
Mutations in the mitochondrial enzyme propionyl-CoA carboxylase (PCC) cause propionic aciduria (PA). Chronic kidney disease (CKD) is a known long-term complication. However, good metabolic control and standard therapy fail to prevent CKD. The pathophysiological mechanisms of CKD are unclear. We investigated the renal phenotype of a hypomorphic murine PA model (Pcca(A138T)) to identify CKD-driving mechanisms. Pcca(A138T) mice show elevated retention parameters and express markers of kidney damage progressing with time. Morphological assessment of the Pcca(A138T) mouse kidneys indicated partial flattening of tubular epithelial cells and focal tubular-cystic dilation. We observed altered renal mitochondrial ultrastructure and mechanisms acting against oxidative stress were active. LC–MS/MS analysis confirmed disease-specific metabolic signatures and revealed disturbances in mitochondrial energy generation via the TCA cycle. Our investigations revealed altered mitochondrial networks shifted towards fission and a marked reduction of mitophagy. We observed a steep reduction of PGC-1-α, the key mediator modulating mitochondrial functions and a counter actor of mitochondrial fission. Our results suggest that impairment of mitochondrial homeostasis and quality control are involved in CKD development in PA. Therapeutic targeting of the identified pathways might help to ameliorate CKD in addition to the current treatment strategies., This study was supported by the Division of Inborn Errors of Metabolism at the Department of Pediatrics, Adolescent Medicine and Neonatology Freiburg and by the Freiburg Center for Rare Diseases. AS and MK were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 431984000—CRC 1453 Nephrogenetics. AS was supported by the Research Commission of the Faculty of Medicine at the University of Freiburg (SCHU2175/21) and by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. MK was supported by Germany’s Excellence Strategy (CIBSS, EXC-2189, project ID 390939984). KAZ was supported by the Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg. The Proteomic Platform—Core Facility was supported by the Medical Faculty of the University of Freiburg to O.S. (2021/A3-Sch). The Translational Metabolomics Core Facility was supported by the Faculty of Medicine, University Hospital Freiburg to LH and US. (Grant Nr. 2023/A7-Han). The research performed in Madrid was funded by Spanish Ministry of Science and Innovation and European Regional Development Fund (Grants PID2019-105344RB-I00/AEI/https://doi.org/10.13039/501100011033 and PID2022-137238OB-I00) and by Fundación Ramón Areces (grant from XX National Call 2020). Open Access funding enabled and organized by Projekt DEAL.